Ki-67蛋白表达在弥漫大B细胞淋巴瘤预后判断中的意义

摘要

Objective To explore the value of Ki-67 protein expressions in patients with diffuse large B-cell lymphoma ( DLBCL) for predicting prognosis. Methods To collect tissue samples from 58 patients with diffuse large B-cell lymphoma ( DL-BCL) , and making tissue chips, classifying them by the expressions of Ki-67 protein, and treating with CHOP chemothera-py. Results The highly or lowly expression of Ki-67 protein in 58 patients with diffuse large B-cell lymphoma ( DLBCL) is not re-lated to gender、age、LDH、outside lymph node lesions、clinical stages and IPI score(P>0. 05)﹒After a median follow-up of 12 months,the survival curves analysis shows that there are 16 months PFS for the groups with highly expression of Ki-67 protein, shorter than the groups with lowly expression of Ki-67 protein which are 27 months PFS,the differences of the PFS in these two groups are statistically significant(P<0. 05). Conclusion The highly expression of Ki-67 protein in patients with diffuse large B-cell lymphoma ( DLBCL) have the poor prognosis.%目的：探讨Ki-67蛋白表达在DLBCL中预后判断的意义。方法收集58例DLBCL患者的手术或活检标本并制作其组织芯片，采用免疫组化对DLBCL进行免疫表型分类，同时检测Ki-67蛋白的表达，并行CHOP方案化疗。结果58例DLBCL患者Ki-67表达高低与性别、年龄、LDH、结外病变、临床分期和IPI评分无关( P>0．05)。中位随访12个月后，生存曲线分析显示Ki-67高表达组中位疾病无进展生存时间( PFS)为16个月，短于Ki-67低表达组27个月，两组PFS差异有统计学意义(P<0．05)。结论在DLBCL患者中Ki-67高表达预后较差。